BioLineRx to Initiate HCV Study - Analyst Blog

A generic image of a person on their smartphone
Credit: Shutterstock photo

BioLineRx ( BLRX ) recently announced that French regulatory authorities have approved the initiation of a phase I/II trial for its oral hepatitis C virus (HCV) infection candidate, BL-8020.

The open-label phase I/II trial will be conducted across two sites in France and will enroll patients infected with HCV who have either failed or relapsed after undergoing treatment with the current standard-of-care. The trial will evaluate the efficacy, safety and tolerability of the candidate in HCV-infected patients. BioLineRx expects to report interim results from the study by year-end.

We believe HCV infection represents a huge commercial opportunity for BioLineRx. As per data from a 2011 report from Decision Resources, approximately 180 million people are suffering from chronic HCV infection globally. The global HCV infection market is expected to be worth $20 billion by 2020 as opposed to $6 billion in 2011.

Apart from BL-8020, other interesting candidates in BioLineRx's pipeline include BL-1020 for schizophrenia (phase II/III), BL-1040 for preventing pathological cardiac remodeling following a myocardial infarction (pivotal CE-Mark registration trial), and BL-5010 for non-surgical removal of skin lesions (phase I/II study complete). We are impressed with the company's efforts to develop its pipeline.

BioLineRx, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharma companies that currently look more attractive include Cytokinetics, Inc. ( CYTK ) and Array BioPharma Inc. ( ARRY ). While Cytokinetics is a Zacks Rank #1 (Strong Buy) stock, Array BioPharma carries a Zacks Rank #2 (Buy). Another pharma stock that looks attractive is Osiris Therapeutics, Inc. ( OSIR ). Osiris is also a Zacks Rank #1 stock.

ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report

BIOLINE RX LTD (BLRX): Get Free Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More